The emerging global consensus suggests that acetaminophen, when used appropriately, does not independently cause neurodevelopmental harm
Suffered Injury or Death After Using GLP-1: Suffered injury after taking a GLP-1 medication, including gastroparesis (stomach paralysis), ileus (intestinal bowel obstruction), intraoperative pulmonary aspiration (entry of liquid or solid material in trachea or lungs), other GI injury that required surgery, non-arteritic anterior ischemic optic neuropathy (NAION) eye injury (sudden, permanent vision loss) or deep vein thrombosis (DVT) and related injuries, including pulmonary embolism (blood clot in lung) and/or death
Current evidence suggests dulaglutide (Trulicity) and extended-release exenatide (Bydureon) generally demonstrate lower nausea rates (approximately 8-12% at lower doses) compared to twice-daily exenatide or higher-dose semaglutide and liraglutide used for weight management
Marketing Adjustments: Shift marketing efforts to highlight the health benefits of certain products, such as low-calorie or low-alcohol options